Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Scopio Labs

Scopio Labs is transforming cell morphology analysis, offering fully digital applications, platforms, and diagnostic ... read more Featured Products: More products

Download Mobile App





First-of-Its-Kind AI-Powered Solution Fully Automates Blood Morphology

By LabMedica International staff writers
Posted on 31 Jul 2025

While Complete Blood Counts (CBCs) have been automated for decades, laboratories still require a human in the loop during the Peripheral Blood Smear (PBS) review process. More...

PBS review remains labor-intensive, complex, and plagued by inefficiencies and variability, resulting in bottlenecks that affect turnaround times, scalability, and ultimately, patient care. These issues are amplified given the ongoing staffing crisis in clinical laboratories. Global workforce shortages, long training cycles, and increased demand for diagnostic tests have left labs struggling to maintain performance. Now, the unveiling of a novel analyzer at ADLM 2025 ushers in a new era of lab automation, analyzing 10x more cells than the current standard of care in blood cell morphology, addressing the global laboratory staffing crisis, and accelerating hematology workflows and efficiencies

Scopio Labs (Parsippany, NJ, USA) is unveiling its groundbreaking Complete Blood Morphology (CBM) analyzer, bringing unprecedented scale, efficiency, and standardization to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics. CBM is built on top of Scopio's proprietary Full-Field technology, leveraging advanced computational imaging and AI-powered analysis to transform the current PBS review workflow into an autonomous, standardized, and clinically relevant process, analyzing 10x more cells than the current standard of care in blood cell morphology. Hematology labs currently utilizing Scopio's Full-Field PBS platform are already alleviating some of the pain points, while laying the essential groundwork for rapid CBM adoption, effectively future-proofing their operations.

"Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result," said Itai Hayut, CEO and Co-founder at Scopio Labs. "This isn't just a small step forward, it could potentially reshape the whole market by changing the workflow, the economics, and creating an entirely new market category. With CBM, the market can evolve from current digital lab solutions that help people make decisions, to a system that's designed to deliver fully automated results with the goal of eliminating the need for routine human morphology review altogether. Beyond that, we also believe that this technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels, which can be used for early detection and monitoring of disease directly from blood."

Related Links:
Scopio Labs


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.